Nilotinib (Tasigna) versus imatinib (Gleevec) for newly diagnosed, previously untreated chronic myelogenous leukemia (Early Chronic Phase)

Research output: Contribution to journal › Article › peer-review

ASJC Scopus subject areas

@article{f2ba1ba3c23b439e951e81d0d5eee1c2,

title = "Nilotinib (Tasigna) versus imatinib (Gleevec) for newly diagnosed, previously untreated chronic myelogenous leukemia (Early Chronic Phase)",

author = "Jorge Cortes",

year = "2009",

month = feb,

language = "English (US)",

volume = "34",

pages = "97",

journal = "P and T",

issn = "1052-1372",

publisher = "MediMedia USA Inc.",

number = "2",

}

TY - JOUR

T1 - Nilotinib (Tasigna) versus imatinib (Gleevec) for newly diagnosed, previously untreated chronic myelogenous leukemia (Early Chronic Phase)

AU - Cortes, Jorge

PY - 2009/2

Y1 - 2009/2

UR - http://www.scopus.com/inward/record.url?scp=62149113360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62149113360&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:62149113360

SN - 1052-1372

VL - 34

SP - 97

JO - P and T

JF - P and T

IS - 2

ER -